Navigation Links
Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
Date:10/29/2013

AMES, Iowa, Oct. 29, 2013 /PRNewswire/ -- Ames, Iowa-based vaccine producer, Harrisvaccines, today announced it has expanded its exclusive license agreement with AlphaVax, Inc. to include all companion animals diseases, in addition to all livestock animal diseases (swine, cattle, horses, poultry, and farmed aquatic animals).

Today's announcement significantly expands the Harrisvaccines product portfolio, transforming it from a primarily production livestock-focused company to a full-service veterinary animal health company, developing vaccines for animals large and small. Harrisvaccines will begin its work in the companion animal realm by developing vaccines for a variety of respiratory diseases in dogs. 

"This is a significant milestone for Harrisvaccines and solidifies our place as an innovative leader in the biologics industry with the ability to utilize this novel, exclusive technology in all preventive veterinary aspects," said Joel Harris, Head of Sales and Marketing for Harrisvaccines.

Harrisvaccines' RNA Particle (RP) Platform technology utilizes a genetic sequence of specific viruses, which can be submitted electronically, to create a vaccine.  Harrisvaccines can use this technology to develop strain-specific vaccines in just a matter of weeks, allowing for rapid response to disease outbreaks. As diseases are constantly evolving, this is crucial to containment and eradication efforts.  In September 2012, Harrisvaccines received its first USDA license for its RP vaccine for H3N2 Influenza Virus in swine, the first vaccine of its kind using this RNA Particle technology to be licensed by a government agency.

Harrisvaccines has developed and commercialized vaccines for some of the most economically significant swine diseases to date, including Porcine Epidemic Diarrhea Virus (PEDV), Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), pandemic H1N1 Swine Influenza Virus, and Porcine Rotavirus A, B, and C. 

"The advantage RP vaccines offer is a platform system that can be used against many different disease-causing agents (viral or bacterial)," said Dr. Hank Harris, president and CEO of Harrisvaccines.  "When a gene sequence is identified from a disease agent that is known to induce a protective immune response, it can quickly be incorporated into the RNA vaccine platform.  The RP vaccine then effectively delivers and expresses the target gene in the animal, resulting in the induction of a protective immune response. By harnessing modern molecular biology, virology and immunology techniques, RP vaccines can be rapidly developed in response to emerging diseases, like Pandemic H1N1 influenza and Porcine Epidemic Diarrhea Virus (PEDV), and re-emerging diseases caused by rapidly mutating viruses such as H3N2 influenza virus and Rotaviruses. This method bypasses the traditional technique of mass vaccine production requiring live microorganisms that is still used by the leading biologic companies today."

About Harrisvaccines
Headquartered in Ames, Iowa, Harrisvaccines focuses on revolutionizing animal health vaccines and enhancing productivity in the swine, cattle, equine, and farmed aquaculture industries. Using state-of-the-art advanced molecular science, Harrisvaccines employs their unique SirraVaxSM RNA Particle (RP) technology platform to develop rapid-response, herd-specific products for animal diseases. To learn more about Harrisvaccines, visit www.harrisvaccines.com.

About AlphaVax
Based in Research Triangle Park, NC, AVX has developed a new generation of vaccine products for diseases that represent significant market opportunities based on its novel, proprietary vector platform technology. AlphaVax is at the forefront of a completely new class of potent biopharmaceutical products aimed to participate in this market with its viral vector technology that has the clear potential to redefine the traditional concept of vaccines. The AlphaVax proprietary viral vector gene expression system has the potential for developing a range of effective vaccines in both cancer and infectious disease.

AlphaVax is focusing the commercial potential of its alphavaccine system in cancer immunotherapy. The development of immunotherapeutic treatments for cancer is a rapidly growing area in which AlphaVax will be taking a lead position in developing new treatment modalities utilizing its proprietary technology. For more information, visit www.alphavax.com.


'/>"/>
SOURCE Harrisvaccines
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Systems, Inc. Secures $20 Million Credit Facility
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Benvenue Medical Secures $25 Million Series D Financing
4. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
5. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
6. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
7. BioMotiv Secures $21 million in Initial Funding
8. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
9. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Zafgen Secures $21 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):